“Atopic Dermatitis Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Atopic Dermatitis Market.
The Atopic Dermatitis Pipeline report embraces in-depth commercial, regulatory, and Atopic Dermatitis clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Atopic Dermatitis drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Atopic Dermatitis Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for Atopic Dermatitis treatment and the aggregate therapies developed by major pharma companies.
It accesses the different Atopic Dermatitis therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the major Atopic Dermatitis companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the Atopic Dermatitis drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Atopic Dermatitis therapeutic market.
Analysis of Emerging Atopic Dermatitis Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Molecule Type
Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Latest Clinical, Commercial, and Regulatory Developments in the Atopic Dermatitis Therapeutics Market
“May 23, 2023, TrialSpark, Inc. announced that the first patient has been dosed in its Phase 2 clinical trial for ASN008-201, a topical sodium channel blocker in development for pruritus associated with atopic dermatitis (AD). This clinical trial is a randomized, double-blind, vehicle-controlled, Phase 2 trial to evaluate the anti-pruritic efficacy, safety, tolerability, and pharmacokinetics of ASN008 in adults with mild to moderate AD (NCT05870865). Topline data for this trial is expected in 2024.
“On May 23 2023, Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) announced enrollment of the first patient in the Phase 2 clinical trial of orally administered RASP modulator ADX‑629, an investigational new drug, for the treatment of atopic dermatitis.”
“On February 10, 2023, Pfizer Inc. (NYSE: PFE) announced that the United States (U.S.) Food and Drug Administration (FDA) approved its supplemental New Drug Application (sNDA) for CIBINQO® (abrocitinib), expanding its indication to include adolescents (12 to
Learn How the Atopic Dermatitis Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @
https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight
Atopic Dermatitis Therapeutics Landscape
There are approx. 100+ key companies developing therapies for Atopic Dermatitis. Currently, Dermavant Sciences is leading the therapeutics market with its Atopic Dermatitis drug candidates in the most advanced stage of clinical development.
Atopic Dermatitis Companies Actively Working in the Therapeutic Market Include:
Akaal Pharma, Allakos Inc., Alphyn Biologics, AnaptysBio, AOBiome, Arcutis Biotherapeutics, Argenx, Dermavant Sciences, E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Genome & Company, GI Innovation, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, Intrinsic Medicine, Kiniksa Pharmaceuticals, MC2 therapeutics, Merck Sharp & Dohme LLC, Pfizer, Qurient Co, Reistone Biopharma, Selection, Shulov Innovate for Science, Sun Pharmaceutical, Suzhou Connect Biopharmaceuticals, Teres Bio, TWi Biotechnology, Vanda Pharmaceuticals, and many others.
Emerging and Marketed Atopic Dermatitis Drugs Covered in the Report Include:
Tapinarof: Dermavant Sciences
Etrasimod: Pfizer
B244: AOBiome
Lirentelimab: Allakos Inc.
QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Rocatinlimab: Amgen/Kyowa Kirin
Lebrikizumab: Dermira/Eli Lilly and Company/Almirall
VTAMA: Dermavant Sciences/ Japan Tobacco Pharmaceutical/ Torii Pharmaceutical
And Many Others
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Atopic Dermatitis Companies Working in the Market @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Atopic Dermatitis Treatment Patterns
4. Atopic Dermatitis – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Atopic Dermatitis Late Stage Products (Phase-III)
7. Atopic Dermatitis Mid-Stage Products (Phase-II)
8. Atopic Dermatitis Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Atopic Dermatitis Discontinued Products
13. Atopic Dermatitis Product Profiles
14. Major Atopic Dermatitis Companies in the Market
15. Key Products in the Atopic Dermatitis Therapeutics Segment
16. Dormant and Discontinued Products
17. Atopic Dermatitis Unmet Needs
18. Atopic Dermatitis Future Perspectives
19. Atopic Dermatitis Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Physiotherapy Equipment Market
“Physiotherapy Equipment Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Physiotherapy Equipment market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Physiotherapy Equipment market.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
